mFLOT

mFLOT is a modified version of the FLOT chemotherapy regimen, which combines four drugs: fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and docetaxel. This combination is primarily used as first-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. The "modified" aspect refers to dose adjustments from the standard FLOT protocol to improve tolerability while maintaining efficacy. The mechanism of action involves multiple cytotoxic effects on rapidly dividing cancer cells: - Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. - Leucovorin enhances the binding of 5-FU to its target enzyme. - Oxaliplatin forms DNA crosslinks leading to apoptosis. - Docetaxel stabilizes microtubules, inhibiting cell division. The regimen is administered intravenously in cycles and has demonstrated improved progression-free survival and overall survival compared with doublet regimens like FOLFOX in clinical trials[2][3]. It is considered a new first-line option for eligible patients with HER2-negative advanced gastric/GEJ cancers[2].

Other names

modified FLOTmodified fluorouracil + leucovorin + oxaliplatin + docetaxel